Shoreline Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Shoreline Biosciences's estimated annual revenue is currently $14.7M per year.
- Shoreline Biosciences's estimated revenue per employee is $188,782
- Shoreline Biosciences's total funding is $186M.
Employee Data
- Shoreline Biosciences has 78 Employees.
- Shoreline Biosciences grew their employee count by 42% last year.
Shoreline Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.8M | 51 | 2% | $53M | N/A |
#2 | $29.6M | 125 | -12% | $110M | N/A |
#3 | $0.4M | 6 | 0% | N/A | N/A |
#4 | $0.8M | 12 | 140% | N/A | N/A |
#5 | $0.5M | 7 | 0% | N/A | N/A |
#6 | $0.4M | 257 | 17% | $236.7M | N/A |
#7 | $21.5M | 114 | -23% | $160M | N/A |
#8 | $0.6M | 10 | 11% | N/A | N/A |
#9 | $3.7M | 21 | 11% | N/A | N/A |
#10 | N/A | 60 | 150% | N/A | N/A |
What Is Shoreline Biosciences?
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
keywords:N/A
$186M
Total Funding
78
Number of Employees
$14.7M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Shoreline Biosciences News
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells...
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells.
SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022.
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapie ...
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology co ...
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.7M | 78 | -2% | N/A |
#2 | $26.8M | 78 | 3% | N/A |
#3 | $11.9M | 79 | -2% | N/A |
#4 | $15.7M | 83 | 63% | $76.5M |
#5 | $12.9M | 86 | 15% | N/A |